je.st
news
Tag: biotech
BioMarin Looks Attractive As Biotech Turns Around
2015-11-16 14:53:47| Biotech - Topix.net
Big FDA news is pending for BioMarin come November 24. Good news on its candidate Drisapersin for muscular dystrophy could catapult shares higher. Biotech looks back in an uptrend, and that makes BioMarin Pharmaceutical look especially attractive now.
Tags: turns
attractive
biotech
biomarin
Premarket Biotech Digest: Mylan's Perrigo Bid, MannKind Rallies, Merck's Setback
2015-11-13 23:38:00| Biotech - Topix.net
Click this Mylan shares are up more than 11% in pre-market trading today as the company's takeover bid for Perrigo is likely to fail. MYL had launched a hostile bid for PRGO earlier this year.
Tags: bid
digest
biotech
setback
Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars
2015-11-12 05:49:58| Biotech - Topix.net
Click this link to find out how much you can save.) Exelixis achieved a major milestone on Tuesday as the company's Cotellic was approved by the FDA as a treatment for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf. Cotellic has already been approved in Switzerland earlier this year.
Tags: call
investor
digest
biotech
Premarket Biotech Digest: Anavex's Results, Gilead's HCV Sales, Sanofi's Strategic Roadmap
2015-11-09 20:25:41| Biotech - Topix.net
Click this link to find out how much you can save.) Anavex is down 8% premarket after a large drop on Friday, just before the Nov 7 results from 32 patients in its phase 2a trial part A. I plan to do a thorough study of this tomorrow, but meanwhile, here are a few quick thoughts for those who are undecided about whether to sell or hold. . First, if you want to follow someone's advice, take it in its entirety, don't do it piecemeal.
Tags: results
sales
strategic
digest
One Reason We Think Biotech Has Bottomed
2015-11-07 03:23:20| Biotech - Topix.net
Scrutiny continues on the biotech sector with price gouging and specialty pharmacies in focus, on the back of the Valeant controversy. It's kind of a tough argument to peddle nowadays that the biotech sector may actually be in the process of bottoming.
Sites : [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] next »